Stanak, M. and Rothschedl, E. (2020): Percutaneous Transvascular Implantation of a Coronary Sinus Reducing Stent. Decision Support Document 121.

Rothschedl, E. and Wolf, S. (2021): Selinexor (Nexpovio®) in combination with dexamethasone for the treatment of relapsed and refractory multiple myeloma (MM). Update November 2022. Oncology Fact Sheet Nr. 39.

Rothschedl, E. and Wolf, S. (2021): Sotorasib (Lumykras®): Sotorasib (Lumykras®) as monotherapy for the treatment of advanced NSCLC with KRAS G12C mutation. Update May 2022. Oncology Fact Sheet Nr. 71.

Rothschedl, E. and Wolf, S. (2022): Tepotinib (Tepmetko®) as monotherapy for the treatment of patients with advanced non-small cell lung cancer (NSCLC). Update May 2022. Oncology Fact Sheet Nr. 73.

Rothschedl, E. and Wolf, S. (2022): Lisocabtagene maraleucel (Breyanzi®) for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBCL) and follicular lymphoma grade 3B (FL3B). Update May 2022. Oncology Fact Sheet Nr. 77.

Rothschedl, E. and Wolf, S. (2022): Avapritinib (Ayvakyt®) for the treatment of advanced systemic mastocytosis (AdvSM). Update September 2022. Oncology Fact Sheet Nr. 78.

Rothschedl, E. and Wolf, S. (2022): Nivolumab (Opdivo®) as monotherapy for the adjuvant treatment of muscle-invasive urothelial carcinoma (MIUC). Update June 2022. Oncology Fact Sheet Nr. 81.

Rothschedl, E. and Wolf, S. (2022): Nivolumab (Opdivo®) in combination with ipilimumab (Yervoy®) for the first-line treatment of patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma (OSCC). Update June 2022. Oncology Fact Sheet Nr. 82.

Rothschedl, E. and Wolf, S. (2022): Nivolumab (Opdivo®) in combination with chemotherapy for the first-line treatment of unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma (OSCC). Update June 2022. Oncology Fact Sheet Nr. 83.

Rothschedl, E. and Wolf, S. (2022): Abemaciclib (Verzenios®) in combination with endocrine therapy for the adjuvant treatment of early breast cancer. Update June 2022. Oncology Fact Sheet Nr. 84.

Rothschedl, E. and Wolf, S. (2022): Ciltacabtagene autoleucel (Carvykti®) for the treatment of relapsed and refractory multiple myeloma (MM). Update June 2022. Oncology Fact Sheet Nr. 86.

Rothschedl, E. and Wolf, S. (2022): Cabozantinib (Cabometyx®) as monotherapy for the treatment of locally advanced or metastatic differentiated thyroid carcinoma (DTC). Update June 2022. Oncology Fact Sheet Nr. 87.

Rothschedl, E. and Wolf, S. (2022): Tisagenlecleucel (Kymriah®) for the treatment of relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy. Update July 2022. Oncology Fact Sheet Nr. 88.

Rothschedl, E. and Wolf, S. (2022): Polatuzumab vedotin (Polivy®) in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for the treatment of previously untreated diffuse large B-cell lymphoma (DLBCL). Update July 2022. Oncology Fact Sheet Nr. 89.

Rothschedl, E. and Wolf, S. (2022): Pembrolizumab (Keytruda®) as monotherapy for the treatment of microsatellite instability-high (MSI‑H) or mismatch repair deficient (dMMR) tumours in adults with unresectable or metastatic colorectal cancer, advanced or recurrent endometrial carcinoma and unresectable or metastatic gastric, small intestine, or biliary cancer. Update July 2022. Oncology Fact Sheet Nr. 90.

Rothschedl, E. and Wolf, S. (2022): Pembrolizumab (Keytruda®) in combination with chemotherapy with or without bevacizumab for the treatment of persistent, recurrent, or metastatic cervical cancer. Update July 2022. Oncology Fact Sheet Nr. 91.

Rothschedl, E. and Wolf, S. (2021): Ripretinib (Qinlock®) for the treatment of patients with advanced gastrointestinal stromal tumour (GIST). Update May 2022. Oncology Fact Sheet Nr. 62.

Rothschedl, E. and Wolf, S. (2022): Mosunetuzumab (Lunsumio®) as monotherapy for the treatment of relapsed or refractory follicular lymphoma (FL) Update September 2022. Oncology Fact Sheet Nr. 92.

Rothschedl, E. and Wolf, S. (2022): Capmatinib (Tabrecta®) as monotherapy for the treatment of advanced non-small cell lung cancer (NSCLC). Update October 2022. Oncology Fact Sheet Nr. 93.

Rothschedl, E. and Wolf, S. (2022): Pembrolizumab (Keytruda®) in combination with chemotherapy as neo-adjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery, for the treatment of locally advanced, or early‑stage triple‑negative breast cancer (TNBC). Update September 2022. Oncology Fact Sheet Nr. 94.

Rothschedl, E. and Wolf, S. (2023): Olaparib (Lynparza®) in combination with abiraterone and prednisone or prednisolone for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Update April 2023. Oncology Fact Sheet Nr. 117.

Rothschedl, E. and Wolf, S. (2022): Selpercatinib (Retsevmo®) as monotherapy for the treatment of advanced RET fusion positive non-small cell lung cancer (NSCLC). Update December 2022. Oncology Fact Sheet Nr. 95.

Rothschedl, E. and Wolf, S. (2022): Atezolizumab (Tecentriq®) as adjuvant treatment following complete resection and platinum-based chemotherapy for patients with non-small cell lung cancer (NSCLC). Update September 2022. Oncology Fact Sheet Nr. 96.

Rothschedl, E. and Wolf, S. (2022): Axicabtagene ciloleucel (Yescarta®) for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL). Update September 2022. Oncology Fact Sheet Nr. 97.

Rothschedl, E. and Wolf, S. (2022): Selinexor (Nexpovio®) in combination with bortezomib and dexamethasone for the treatment of multiple myeloma (MM). Update October 2022. Oncology Fact Sheet Nr. 98.

Rothschedl, E. and Wolf, S. (2022): Pembrolizumab (Keytruda®) as monotherapy for the adjuvant treatment of adults and adolescents aged 12 years and older with stage IIB, IIC or III melanoma who have undergone complete resection. Update October 2022. Oncology Fact Sheet Nr. 99.

Rothschedl, E. and Wolf, S. (2022): Enfortumab vedotin (Padcev®) as monotherapy for the treatment of patients with locally advanced or metastatic urothelial cancer. Update June 2022. Oncology Fact Sheet Nr. 85.

Rothschedl, E. and Wolf, S. (2022): Asciminib (Scemblix®) for the treatment of Philadelphia chromosome‑positive (Ph+) chronic myeloid leukaemia (CML) in chronic phase (CP). Update November 2022. Oncology Fact Sheet Nr. 101.

Rothschedl, E. and Wolf, S. (2022): Trastuzumab deruxtecan (Enhertu®) as monotherapy for the treatment of unresectable or metastatic HER2 positive breast cancer. Update November 2022. Oncology Fact Sheet Nr. 102.

Rothschedl, E. and Wolf, S. (2022): Ibrutinib (Imbruvica®) in combination with venetoclax for the treatment of previously untreated chronic lymphocytic leukaemia (CLL). Update November 2022. Oncology Fact Sheet Nr. 103.

Rothschedl, E. and Wolf, S. (2022): Olaparib (Lynparza®) as monotherapy or in combination with endocrine therapy for the adjuvant treatment of patients with germline BRCA1/2-mutations who have HER2-negative, high risk early breast cancer. Update December 2022. Oncology Fact Sheet Nr. 104.

Rothschedl, E. and Wolf, S. (2022): Melphalan flufenamide (Pepaxti®) with dexamethasone for the treatment of multiple myeloma (MM). Update October 2022. Oncology Fact Sheet Nr. 100.

Rothschedl, E. and Wolf, S. (2022): Degarelix (Firmagon®) as a neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone-dependent prostate cancer. Oncology Fact Sheet Nr. 65.

Rothschedl, E. and Wolf, S. (2022): Degarelix (Firmagon®) for treatment of high-risk localised and locally advanced hormone-dependent prostate cancer in combination with radiotherapy. Oncology Fact Sheet Nr. 66.

Rothschedl, E. and Wolf, S. (2022): Relatlimab/nivolumab (Opdualag®) for the first line treatment of advanced melanoma in adults and adolescents 12 years of age and older with tumour cell PD-L1 expression < 1%. Update December 2022. Oncology Fact Sheet Nr. 105.

Rothschedl, E. and Wolf, S. (2022): Autologous anti-CD19-transduced CD3+ cells (Tecartus®) for the treatment of adult patients 26 years of age and above with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL). Update December 2022. Oncology Fact Sheet Nr. 106.

Rothschedl, E. and Wolf, S. (2022): Teclistamab (Tecvayli®) as monotherapy for the treatment of patients with relapsed and refractory multiple myeloma (MM) who have received at least three prior therapies. Update December 2022. Oncology Fact Sheet Nr. 107.

Rothschedl, E. and Wolf, S. (2022): Selpercatinib (Retsevmo®) as monotherapy for the treatment of adults and adolescents 12 years and older with advanced RET mutant medullary thyroid cancer (MTC). Update March 2023. Fact Sheet Nr. 108.

Rothschedl, E. and Wolf, S. and Grössmann, N. (2021): Avapritinib (Ayvakyt®) for the treatment of gastrointestinal stromal tumours (GIST). Update September 2022. Oncology Fact Sheet Nr. 16.

Rothschedl, E. and Wolf, S. (2022): Loncastuximab tesirine (Zynlonta®) as monotherapy for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL). Update July 2023. Fact Sheet Nr. 109.

Rothschedl, E. and Wolf, S. (2022): Zanubrutinib (Brukinsa®) as monotherapy for the treatment of marginal zone lymphoma (MZL). Update March 2023. Fact Sheet Nr. 110.

Rothschedl, E. and Wolf, S. (2022): Axicabtagene ciloleucel (Yescarta®) for the treatment of patients with diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL). Update March 2023. Fact Sheet Nr. 111.

Rothschedl, E. and Wolf, S. (2022): Zanubrutinib (Brukinsa®) as monotherapy for the treatment of adult patients with chronic lymphocytic leukaemia (CLL). Update March 2023. Fact Sheet Nr. 112.

Rothschedl, E. and Wolf, S. (2022): Cemiplimab (Libtayo®) as monotherapy for the treatment of recurrent or metastatic cervical cancer. Update March 2023. Fact Sheet Nr. 113.

Rothschedl, E. and Wolf, S. (2022): Lutetium (177Lu) vipivotide tetraxetan (Pluvicto®) in combination with androgen deprivation therapy (ADT) with or without androgen receptor (AR) pathway inhibition for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Update April 2023. Oncology Fact Sheet Nr. 114.

Rothschedl, E. and Wolf, S. and Grössmann, N. (2021): Moxetumomab pasudotox (Lumoxiti®) for the treatment of patients with relapsed or refractory hairy cell leukaemia (HCL). Withdrawal of the marketing authorisation in the European Union. Update November 2022. Oncology Fact Sheet Nr. 35.

Rothschedl, E. and Wolf, S. (2022): Relugolix (Orgovyx®) for the treatment of advanced hormone-sensitive prostate cancer. Update November 2022. Oncology Fact Sheet Nr. 80.

Rothschedl, E. and Wolf, S. (2022): Trastuzumab deruxtecan (Enhertu®) as monotherapy for the treatment of adult patients with advanced HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma. Update April 2023. Oncology Fact Sheet Nr. 115.

Rothschedl, E. and Grössmann, N. (2023): Pirtobrutinib (JaypircaTM) as monotherapy for the treatment of relapsed or refractory (R/R) mantle cell lymphoma (MCL). Update December 2023. Fact Sheet Nr. 131.

Rothschedl, E. and Wolf, S. (2022): Durvalumab (Imfinzi®) in combination with gemcitabine and cisplatin for the first‑line treatment of unresectable or metastatic biliary tract cancer (BTC). Update April 2023. Oncology Fact Sheet Nr. 116.

Rothschedl, E. and Grössmann, N. (2023): Glofitamab (Columvi®) as monotherapy for the treatment of relapsed or refractory (R/R) diffuse large B‑cell lymphoma (DLBCL). Update February 2024. Fact Sheet Nr. 130.

Rothschedl, E. and Wolf, S. (2023): Tremelimumab (Imjudo®) in combination with durvalumab for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (HCC). Update July 2023. Oncology Fact Sheet Nr. 118.

Rothschedl, E. and Wolf, S. (2023): Tremelimumab AstraZeneca in combination with durvalumab and platinum-based chemotherapy for the first-line treatment of metastatic non-small cell lung cancer (NSCLC). Update April 2023. Oncology Fact Sheet Nr. 119.

Rothschedl, E. and Wolf, S. (2023): Trastuzumab deruxtecan (Enhertu®) as monotherapy for the treatment of adult patients with unresectable or metastatic HER2‑low breast cancer. Update April 2023. Oncology Fact Sheet Nr. 120.

Rothschedl, E. and Wolf, S. (2023): Nadofaragene firadenovec (Adstiladrin®) for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumours. Update June 2023. Fact Sheet Nr. 121.

Rothschedl, E. and Wolf, S. (2023): Oportuzumab monatox for the treatment of noninvasive urothelial carcinoma in situ (CIS) previously treated with Bacillus Calmette-Guérin (BCG). Update June 2023. Fact Sheet Nr. 122.

Rothschedl, E. and Wolf, S. (2022): Tebentafusp (Kimmtrak®) as monotherapy for the treatment of human leukocyte antigen (HLA) A*02:01 positive patients with unresectable or metastatic uveal melanoma. Update March 2023. Fact Sheet Nr. 79.

Rothschedl, E. and Wolf, S. (2023): Niraparib/abiraterone acetate (Akeega®) for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Update July 2023. Fact Sheet Nr. 125.

Rothschedl, E. and Wolf, S. (2023): Ivosidenib (Tibsovo®, Tidhesco® ) in combination with azacitidine for the treatment of newly diagnosed acute myeloid leukaemia (AML). Update June 2023. Fact Sheet Nr. 126.

Rothschedl, E. and Grössmann, N. (2023): Ivosidenib (Tibsovo®) monotherapy for the treatment of locally advanced or metastatic cholangiocarcinoma. Update February 2024. Fact Sheet Nr. 127.

Rothschedl, E. and Wolf, S. (2023): Cemiplimab (Libtayo®) in combination with platinum‐based chemotherapy for the first‐line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC). Update June 2023. Fact Sheet Nr. 128.

Rothschedl, E. and Wolf, S. (2023): Futibatinib (Lytgobi®) for the treatment of locally advanced or metastatic cholangiocarcinoma. Update July 2023. Fact Sheet Nr. 132.

Rothschedl, E. and Wolf, S. (2023): Lisocabtagene maraleucel (Breyanzi®) for the treatment of diffuse large B-cell lymphoma (DLBCL), high grade B cell lymphoma (HGBCL), primary mediastinal large B-cell lymphoma (PMBCL) and follicular lymphoma grade 3B (FL3B). Update July 2023. Fact Sheet Nr. 129.

Rothschedl, E. and Wolf, S. (2023): Nivolumab (Opdivo®) in combination with platinum-based chemotherapy for the neoadjuvant treatment of resectable non-small cell lung cancer (NSCLC). Update October 2023. Fact Sheet Nr. 133.

Rothschedl, E. and Wolf, S. (2023): Piflufolastat (18F) (Pylclari®) for the diagnosis of prostate cancer. Update October 2023. Fact Sheet Nr. 134.

Rothschedl, E. and Wolf, S. (2023): Darolutamide (Nubeqa®) in combination with docetaxel and androgen deprivation therapy (ADT) for the treatment of metastatic hormone‑sensitive prostate cancer (mHSPC). Update June 2023. Fact Sheet Nr. 123.

Rothschedl, E. and Grössmann, N. (2023): Tremelimumab (Imjudo®) with durvalumab (Imfinzi®) and platinum-based chemotherapy for the first-line treatment of metastatic non-small cell lung cancer (NSCLC). Update October 2023. Fact Sheet Nr. 135.

Rothschedl, E. and Grössmann, N. (2023): Trifluridine/tipiracil (Lonsurf®, TAS-02) with bevacizumab for the treatment of metastatic colorectal cancer (CRC). Update October 2023. Fact Sheet Nr. 136.

Rothschedl, E. and Grössmann, N. (2023): Sacituzumab govitecan (Trodelvy®) for the treatment of unresectable or metastatic hormone receptor-positive, HER2-negative breast cancer. Update October 2023. Fact Sheet Nr. 137.

Rothschedl, E. and Grössmann, N. (2023): Crisantaspase (Enrylaze®) for the treatment of acute lymphoblastic leukaemia (ALL) and lymphoblastic lymphoma (LBL). Update July/August 2023. Fact Sheet Nr. 138.

Rothschedl, E. and Grössmann, N. (2023): Cedazuridine/decitabine (Inaqovi®) for the treatment of newly diagnosed acute myeloid leukaemia (AML). Update December 2023. Fact Sheet Nr. 139.

Rothschedl, E. and Grössmann, N. (2023): Elacestrant (Orserdu®) monotherapy for the treatment of oestrogen receptor (ER)‑positive, HER2-negative, locally advanced or metastatic breast cancer. Update December 2023. Fact Sheet Nr. 140.

Rothschedl, E. and Grössmann, N. (2023): Talquetamab (Talvey®) for the treatment of adult patients with relapsed and refractory multiple myeloma (MM). Update December 2023. Fact Sheet Nr. 141.

Rothschedl, E. and Grössmann, N. (2023): Epcoritamab (Tepkinly®) as monotherapy for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Update February 2024. Fact Sheet Nr. 142.

Rothschedl, E. and Grössmann, N. (2020): Belantamab mafodotin (Blenrep®) as monotherapy for the treatment of relapsed or refractory multiple myeloma (MM). Update February 2024. Oncology Fact Sheet Nr. 17.

Rothschedl, E. and Grössmann, N. (2023): Tislelizumab (Tevimbra®) as monotherapy for the treatment of unresectable, locally advanced, or metastatic oesophageal squamous cell carcinoma (OSCC). Update February 2024. Fact Sheet Nr. 143.

Rothschedl, E. and Grössmann, N. (2023): Nivolumab (Opdivo®) as monotherapy for the adjuvant treatment of Stage IIB or IIC melanoma, or melanoma with involvement of lymph nodes or metastatic disease. Update July/August 2023. Fact Sheet Nr. 144.

Rothschedl, E. and Grössmann, N. (2023): Pembrolizumab (Keytruda®) with trastuzumab, fluoropyrimidine and platinum-containing chemotherapy for the first-line treatment of locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction (GEJ) adenocarcinoma. Update July/August 2023. Fact Sheet Nr. 145.

Rothschedl, E. and Grössmann, N. (2023): Brentuximab vedotin (Adcetris®) in combination with doxorubicin, vinblastine and dacarbazine for previously untreated CD30+ Stage III or IV Hodgkin lymphoma. Update February 2024. Fact Sheet Nr. 146.

Rothschedl, E. and Grössmann, N. (2023): Melphalan flufenamide (Pepaxti®) in combination with dexamethasone for the treatment of multiple myeloma (MM). Fact Sheet Nr. 149.

Rothschedl, E. and Grössmann, N. (2023): Trastuzumab deruxtecan (Enhertu®) as monotherapy for the treatment of patients with advanced non-small cell lung cancer (NSCLC) whose tumours have an activating HER2 (ERBB2) mutation. Update April 2024. Fact Sheet Nr. 147.

Rothschedl, E. and Grössmann, N. (2023): Pembrolizumab (Keytruda®) as monotherapy for the adjuvant treatment of non-small cell lung carcinoma (NSCLC). Update April 2024. Fact Sheet Nr. 148.

Rothschedl, E. and Grössmann, N. (2023): Quizartinib (Vanflyta®) in combination with standard cytarabine and anthracycline induction and cytarabine consolidation chemotherapy, followed by single-agent maintenance therapy for patients with newly diagnosed acute myeloid leukaemia (AML). Update February 2024. Fact Sheet Nr. 150.

Rothschedl, E. and Grössmann, N. (2023): Zanubrutinib (Brukinsa®) with obinutuzumab for the treatment of refractory or relapsed follicular lymphoma (FL). Fact Sheet Nr. 151.

Rothschedl, E. and Grössmann, N. (2023): Elranatamab (Elrexfio®) as monotherapy for the treatment of relapsed and refractory multiple myeloma (MM). Fact Sheet Nr. 152.

Rothschedl, E. and Grössmann, N. (2023): Durvalumab (Imfinzi®) as monotherapy for the first line treatment of advanced or unresectable hepatocellular carcinoma (HCC). Fact Sheet Nr. 153.

Rothschedl, E. and Grössmann, N. (2023): Dostarlimab (Jemperli®) with carboplatin and paclitaxel for the treatment of mismatch repair deficient (dMMR)/ microsatellite instability high (MSI-H) primary advanced or recurrent endometrial cancer (EC). Fact Sheet Nr. 154.

Rothschedl, E. and Grössmann, N. (2023): Pembrolizumab (Keytruda®) with fluoropyrimidine and platinum-containing chemotherapy for the first-line treatment of locally advanced unresectable or metastatic HER2-negative gastric or gastro-oesophageal junction adenocarcinoma. Fact Sheet Nr. 155.

Rothschedl, E. and Grössmann, N. (2023): Rucaparib (Rubraca®) as monotherapy for the maintenance treatment of advanced high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer. Fact Sheet Nr. 156.

Rothschedl, E. and Grössmann, N. (2023): Avapritinib (Ayvakyt®) for the treatment of indolent systemic mastocytosis (ISM). Fact Sheet Nr. 157.

Rothschedl, E. and Grössmann, N. (2023): Pembrolizumab (Keytruda®) with gemcitabine and cisplatin for the first-line treatment of locally advanced unresectable or metastatic biliary tract carcinoma (BTC). Fact Sheet Nr. 158.

Rothschedl, E. and Grössmann, N. (2023): Adagrasib (Krazati®) as monotherapy for the treatment of advanced non-small cell lung cancer (NSCLC). Fact Sheet Nr. 159.

Rothschedl, E. and Grössmann, N. (2023): Momelotinib (Omjjara®) for the treatment of disease-related splenomegaly or symptoms in adult patients with moderate to severe anaemia who have primary myelofibrosis (PMF), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis. Fact Sheet Nr. 160.

Rothschedl, E. and Grössmann, N. (2023): Talazoparib (Talzenna®) in combination with enzalutamide for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Fact Sheet Nr. 161.

Rothschedl, E. and Grössmann, N. (2024): Idecabtagene vicleucel (Abecma®) for the treatment of adult patients with relapsed and refractory multiple myeloma (MM) who have received at least two prior therapies. Fact Sheet Nr. 162.

Rothschedl, E. and Grössmann, N. (2024): Selpercatinib (Retsevmo®) as monotherapy is indicated for the treatment of adults and adolescents with advanced RET fusion-positive thyroid cancer. Fact Sheet Nr. 163.

Rothschedl, E. and Grössmann, N. (2024): Tislelizumab (Tizveni®) in monotherapy or in combination with chemotherapy for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC). Fact Sheet Nr. 164.

Rothschedl, E. and Grössmann, N. (2024): Retifanlimab (Zynyz®) as monotherapy for the first line treatment of patients with metastatic or recurrent locally advanced Merkel cell carcinoma. Fact Sheet Nr. 165.

Rothschedl, E. and Grössmann, N. (2024): Ciltacabtagene autoleucel (Carvykti®) for the treatment of relapsed and refractory multiple myeloma (MM). Fact Sheet Nr. 166.

Rothschedl, E. and Grössmann, N. (2024): Pembrolizumab (Keytruda®) as pre- and post-operative treatment of resectable non small cell lung carcinoma (NSCLC). Fact Sheet Nr. 167.

Rothschedl, E. and Grössmann, N. (2024): Irinotecan hydrochloride trihydrate (Onivyde® pegylated liposomal) in combination with oxaliplatin, 5 fluorouracil (5 FU) and leucovorin (LV) for the first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas. Fact Sheet Nr. 168.

Rothschedl, E. and Grössmann, N. (2024): Selpercatinib (Retsevmo®) as monotherapy for the treatment of advanced rearranged during transfection (RET) fusion-positive solid tumours. Fact Sheet Nr. 169.

Rothschedl, E. and Grössmann, N. (2024): Enzalutamide (Xtandi®) as monotherapy or in combination with androgen deprivation therapy (ADT) for the treatment of high risk biochemical recurrent (BCR) non-metastatic hormone sensitive prostate cancer (nmHSPC). Fact Sheet Nr. 170.

Grössmann, N. and Rothschedl, E. and Wolf, S. (2018): Horizon Scanning in Oncology 35th Prioritisation – 2nd quarter 2018. HSO: 35th Prioritisation.

Rothschedl, E. and Nachtnebel, A. (2013): Aflibercept (Zaltrap®) in addition to FOLFIRI for the 2nd line therapy of metastatic colorectal cancer. DSD: Horizon Scanning in Oncology 38.

Rothschedl, E. and Nachtnebel, A. (2015): Bevacizumab (Avastin®) in combination with chemotherapy as second-line therapy for HER2-negative, locally recurrent or metastatic breast cancer that has progressed after first-line treatment with bevacizumab plus chemotherapy. DSD: Horizon Scanning in Oncology 51.

Rothschedl, E. and Nachtnebel, A. (2013): Regorafenib (Stivarga®) for heavily pretreated patients with metastatic colorectal cancer (mCRC). DSD: Horizon Scanning in Oncology 40.

Rothschedl, E. (2019): Enzalutamide (Xtandi®) in addition to standard first-line therapy in men with metastatic hormone-sensitive prostate cancer (mHSPC). DSD: Horizon Scanning in Oncology 90.

Rothschedl, E. and Nachtnebel, A. (2015): Defibrotide for the treatment and prophylaxis of hepatic veno-occlusive disease. Decision Support Document 84.

Grössmann, N. and Rothschedl, E. and Wolf, S. (2019): Horizon Scanning in Oncology 39th Prioritisation – 2nd quarter 2019 . HSO: 39th Prioritisation.

Rothschedl, E. (2018): Enzalutamide (Xtandi®) in patients with nonmetastatic, castration-resistant prostate cancer (CRPC). DSD: Horizon Scanning in Oncology 84.

Rothschedl, E. and Joppi, R. and Poggiani, C. (2014): Idelalisib (Zydelig®) in addition to rituximab for the treatment of relapsed chronic lymphocytic leukaemia. DSD: Horizon Scanning in Oncology 49.

Rothschedl, E. (2018): Nivolumab (Opdivo®) in combination with ipilimumab (Yervoy®) for the first-line treatment of patients with advanced RCC. DSD: Horizon Scanning in Oncology 82.

Rothschedl, E. (2019): Olaparib (Lynparza®) as first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer. DSD: Horizon Scanning in Oncology 86.

Grössmann, N. and Wolf, S. and Rothschedl, E. (2019): Horizon Scanning in Oncology 38th Prioritisation – 1st quarter 2019. HSO: 38th Prioritisation.

Rothschedl, E. and Nachtnebel, A. (2016): Bevacizumab (Avastin®) in addition to standard chemotherapy for the first-line treatment of ovarian cancer. DSD: Horizon Scanning in Oncology 56.

Rothschedl, E. (2019): Darolutamide for the treatment of patients with nonmetastatic castration-resistant prostate cancer (CRPC). DSD: Horizon Scanning in Oncology 88.

Grössmann, N. and Rothschedl, E. and Wolf, S. (2019): Horizon Scanning in Oncology 41st Prioritisation – 4th quarter 2019. HSO: 41st Prioritisation.

Rothschedl, E. and Nachtnebel, A. (2015): Horizon Scanning in Oncology: Results of the 22nd Prioritisation – 1st quarter 2015. HSO: 22nd Prioritisation.

Rothschedl, E. and Nachtnebel, A. (2015): Horizon Scanning in Oncology: Results of the 24th Prioritisation – 3rd quarter 2015. HSO: 24th Prioritisation.

Grössmann, N. and Rothschedl, E. and Wolf, S. (2018): Horizon Scanning in Oncology 37th Prioritization – 4th quarter 2018. HSO: 37th Prioritisation.

Grössmann, N. and Rothschedl, E. and Wolf, S. (2019): Horizon Scanning in Oncology 40th Prioritisation – 3rd quarter 2019. HSO: 40th Prioritisation.

Rothschedl, E. and Nachtnebel, A. (2015): Pembrolizumab (Keytruda®) for the treatment of advanced melanoma. DSD: Horizon Scanning in Oncology 55.

Rothschedl, E. (2018): Rituximab (MabThera®) after autologous stem-cell transplantation (ASCT) in mantle cell lymphoma (MCL). DSD: Horizon Scanning in Oncology 79.

Rothschedl, E. and Nachtnebel, A. (2014): Bevacizumab (Avastin®) as maintenance therapy after first progression on bevacizumab for patients with advanced colorectal carcinoma. DSD: Horizon Scanning in Oncology 46.

Rothschedl, E. and Nachtnebel, A. (2015): Horizon Scanning in Oncology 23rd Prioritisation – 2nd quarter 2015. HSO: 23rd Prioritisation.

Zechmeister-Koss, I. and Rothschedl, E. (2015): Fully bioresorbable scaffolds for coronary artery disease. Decision Support Document 81.

Grössmann, N. and Rothschedl, E. and Wolf, S. (2018): Horizon Scanning in Oncology 36th Prioritisation – 3rd quarter 2018. HSO: 36th Prioritisation.

Rothschedl, E. (2018): Daratumumab (Darzalex®) in combination with bortezomib, melphalan and prednisone for untreated myeloma. DSD: Horizon Scanning in Oncology 81.